- Home
- ADEA vs VIR Comparison
ADEA vs VIR Comparison
Compare ADEA & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- VIR
- Stock Information
- Founded
- ADEA 1990
- VIR 2016
- Country
- ADEA United States
- VIR United States
- Employees
- ADEA N/A
- VIR N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- ADEA Technology
- VIR Health Care
- Exchange
- ADEA Nasdaq
- VIR Nasdaq
- Market Cap
- ADEA 1.5B
- VIR 1.4B
- IPO Year
- ADEA N/A
- VIR 2019
- Fundamental
- Price
- ADEA $17.23
- VIR $9.57
- Analyst Decision
- ADEA Strong Buy
- VIR Buy
- Analyst Count
- ADEA 3
- VIR 6
- Target Price
- ADEA $18.33
- VIR $34.83
- AVG Volume (30 Days)
- ADEA 565.8K
- VIR 1.2M
- Earning Date
- ADEA 02-18-2025
- VIR 02-26-2025
- Dividend Yield
- ADEA 1.53%
- VIR N/A
- EPS Growth
- ADEA N/A
- VIR N/A
- EPS
- ADEA 0.57
- VIR N/A
- Revenue
- ADEA $376,024,000.00
- VIR $78,618,000.00
- Revenue This Year
- ADEA N/A
- VIR N/A
- Revenue Next Year
- ADEA $10.09
- VIR N/A
- P/E Ratio
- ADEA $30.04
- VIR N/A
- Revenue Growth
- ADEA N/A
- VIR N/A
- 52 Week Low
- ADEA $9.68
- VIR $6.56
- 52 Week High
- ADEA $14.75
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- ADEA 83.43
- VIR 48.60
- Support Level
- ADEA $13.20
- VIR $9.54
- Resistance Level
- ADEA $17.46
- VIR $9.97
- Average True Range (ATR)
- ADEA 0.57
- VIR 0.55
- MACD
- ADEA 0.51
- VIR -0.08
- Stochastic Oscillator
- ADEA 95.53
- VIR 39.89
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property Licensing (IP). In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.